Effect of Remote Glucose Monitoring Utilizing Computerized Insulin Dose Adjustment Algorithms: A Pilot Project
Tóm tắt
Primary care physicians are often challenged to adjust insulin doses. To facilitate this process, we evaluated in a safety net clinic the work flow and glycemic effects of remote glucose monitoring utilizing Federal Drug Administration (FDA) cleared, Conformité Européenne (CE) registered software that contained computerized algorithms for insulin dose adjustments to help clinicians make dosing decisions for insulin-requiring patients. Patients taking insulin for at least 6 months with HbA1c levels of at least 8.0% measured glucose levels with a meter attached to their smartphones. Readings were automatically transmitted to a secure, Health Insurance Portability and Accountability Act (HIPAA)-approved server. Values were analyzed every 2–3 weeks and reports, including recommendations for insulin dose changes, were sent to a clinic nurse practitioner (NP) who modified or accepted the recommendations. A staff person contacted patients with the new doses determined by the NP. Insulin regimens included basal alone (N = 11), basal/bolus (N = 14), and self-mixed/split (N = 3). Baseline HbA1 levels of 10.0% fell to 8.1% at 3 months (N = 28) and 7.6% at 6 months (N = 17) without any clinic visits for dose adjustments. There were 268 reports which allowed providers to see 268 other patients during these avoided clinic visits. The NP agreed with 82% of the recommendations. The total doses of insulin increased by 24%. No patient experienced severe hypoglycemia or visited an emergency department for hypoglycemia. Remote glucose monitoring utilizing computerized insulin dose adjustment algorithms saved time for both providers and patients while effectively improving glycemia. The Leonard M. Lipman Charitable Trust and Mellitus Health.
Tài liệu tham khảo
U.K. Prospective Diabetes Study Group. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–58.
Holman RR. Assessing the potential for α-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract. 1998;40(Suppl):S21–5.
Selvin E, Porrinello CM, et al. Trends in insulin use and diabetes control in the U.S.: 1988–1994 and 1999–2012. Diabetes Care. 2016;39:e33–5.
Davidson JA. The increasing role of primary physicians in caring for patients with type 2 diabetes mellitus. Mayo Clin Proc. 2010;85(Suppl 12):S3–4.
Jeavons D, Hungin APS, Cornford CS. Patients with poorly controlled diabetes in primary care: healthcare clinicians’ beliefs and attitudes. Postgrad Med J. 2006;82:347–50.
Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32:1342–9.
Cuddihy RM, Philis-Tsimikas A, Nazeri A. Type 2 diabetes care and insulin intensification: is a more multidisciplinary approach needed? Results from the MODIFY survey. Diabetes Educ. 2011;37:111–23.
Patrick AR, Fischer MA, Choudry NK, et al. Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. J Gen Intern Med. 2013;29:320–7.
Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18:401–9.
Ascher-Svanum H, Lage M, et al. Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2014;5:225–42.
Bonafede M, Chandran A, DiMano S, et al. Medication usage, treatment intensification, and medical cost in patients with type 2 diabetes: a retrospective database study. BMJ Open Diabetes Res Care. 2016;4:e000189. https://doi.org/10.1136/bmjdrc-2015-00189.
Mata-Cases M, Franch-Nadal J, Real J, et al. Therapeutic inertia in patients treated with two or more antidiabetics in primary care: factors predicting intensification of treatment. Diabetes Obes Metab. 2018;20:103–12.
LeBlanc ES, Rosales AG, Kachroo S, et al. Provider beliefs about diabetes treatment have little impact on glycemic control of their patients with diabetes. BMJ Open Diabetes Res Care. 2015;3:e000062. https://doi.org/10.1136/bmjdrc-2014-00062.
Ellis K, Mulnier H, Forbes A. Perceptions of insulin use in type 2 diabetes in primary care: a thematic synthesis. BMC Fam Pract. 2018;19(1):70. https://doi.org/10.1186/s12875-018-0753-2.
Bashan E, Herman WH, Hodish I. Are glucose readings sufficient to adjust insulin dosage? Diabetes Tech Therap. 2011;13:85–92.
Davidson MB, Hsia S. Glycemia. In: Meeting the American Diabetes Association standards of care: an algorithmic approach to clinical care of the diabetes patient. American Diabetes Association, Alexandria, VA, 2017, pp. 76–91.
Davidson MB. Insulin therapy: a personal approach. Clin Diabetes. 2015;33:123–35.
Food and Drug Administration (FDA). Regulation Number 21 CFR 868 1890: Submission # k160673.
Medicines & Healthcare Products Regulatory Agency (MHRA), Reference CA015516.
Davidson MB, Lewis G. Effect of data management on a central server on HbA1c levels in insulin-requiring patients. Diabetes Care. 2000;23:706–7.
Davidson MB, Blanco-Castellanos M, Duran P. Integrating nurse-directed diabetes management into a primary care setting. Am J Manag Care. 2010;16:652–6.
Brazeau AS, Mircescu H, Leroux C, et al. Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes. Diabetes Res Clin Pract. 2013;99:19–23.
Meade LT, Rushton WE. Accuracy of carbohydrate counting in adults. Clin Diabetes. 2016;34:142–7.
Bell KJ, Toschi E, Steil GM, et al. Optimized mealtime insulin dosing for fat and protein in type 1 diabetes: application of a model-based approach to derive insulin doses for open-loop diabetes management. Diabetes Care. 2016;39:1631–4.
Paterson MA, Smart CEM, Lopez PE, et al. Increasing the protein quantity in a meal results in dose-dependent effects on postprandial glucose levels in individuals with type 1 diabetes mellitus. Diabetic Med. 2017;34:851–4.
Huckvale K, Adomaviciute S, Prieto JT, et al. Smartphone apps for calculating insulin dose: a systematic assessment. BMC Med. 2015;13:106. https://doi.org/10.1186/s12916-015-0314-7.
Davidson MB. Delayed response to NPH insulin. Diabetes Res Clin Pract. 2004;64:229.
Davidson MB. Delayed response to NPH insulin. In: Draznin B, editor. Diabetes case files: real problems, practical solutions. Alexandria: American Diabetes Association; 2014. p. 267–70.
Davidson MB. Delayed response to U-500 regular insulin. Clin Diabetes. 2018;36:77–9.
Harper R, Donnelly R, Bi Y, et al. Dynamics in insulin requirements and treatment safety. J Diabetes Compl. 2016;30:1333–8.
Edelman SV, Liu R, Johnson J, Glass LG. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. Diabetes Care. 2014;37:2132–40.
Hodish I. Insulin therapy, weight gain and prognosis. Diabetes Obes Metab. 2018;20:2085–92.
Calvert MJ, McManis RJ, Freemantle N. Management of type 2 diabetes with multiple oral hyperglycaemic agents or insulin in primary care retrospective cohort study. Br J Gen Pract. 2007;57:455–60.
Rubino A, McQuay LJ, Gough SC, et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med. 2007;24:1412–8.
Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control. J Gen Intern Med. 2007;22:453–8.
Khunti K, Wolden MI, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411–7.
Home P, Naggar NE, Khamseh M, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res Clin Pract. 2011;94:352–63.
Harris SB, Kapor J, Lank CN, et al. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician. 2010;56:e418–24.
Yang Y, Lang Q, Jackson SL, et al. Nurse practitioners, physician assistants, and physicians are comparable in managing the first five years of diabetes. Am J Med. 2018;131:276–83.
Balkau B, Calvi-Gries F, Freemantle N, Vincent M, Pilorget V, Home PD. Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: the CREDIT study. Diabetes Res Clin Pract. 2015;108:432–40.
Ziemer DC, Miller CD, Rhee MK, et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ. 2005;31:564–71.
Chen Y, Abbott S, Nguyen M, et al. Glycemic control of insulin treated patients across the U.S.: epidemiologic analysis of a commercially insured population. Diabetes. 2013;62(Suppl 1):A704.
American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41:917–28.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
Gilmer TP, O’Connor PJ, Manning WG, et al. The cost to health plans of poor glycemic control. Diabetes Care. 1997;20:1847–53.